Abbott And Coroventis Partner To Address Often-Overlooked Microvascular Dysfunction
Coroventis’ CoroFlow software allows Abbott’s PressureWire X to diagnose coronary microvascular dysfunction caused by invisible blockages in the heart’s smallest arteries.
You may also be interested in...
The company’s survey of more than 1,400 patients, physicians and administrators showed patients want more personalized care and physicians want more data.
The US FDA's Circulatory System Devices Panel will meet on 27 October to evaluate Neovasc’s Reducer device, a minimally invasive treatment for drug-refractory angina.
St. Jude Medical acquired two privately-held firms just before the New Year for a total of $550 million, gaining tools for artery lesion assessment and precise interventional procedure navigation, among other technologies